

application U.S. Ser. No. 08/788,800 claiming priority thereto under 35 U.S.C. §119(e).¹

Therefore, there is continuity of disclosure throughout the chain of applications extending from the above-identified application to parent provisional application U.S. Ser. No. 60/093,038.

The named inventors of the above-identified application are Martin M. Bednar, Cordell E. Gross and G. Roger Thomas. The named inventors of parent application U.S. Ser. No. 09/251,652 are Hal V. Barron, Paula M. Jardieu and G. Roger Thomas. Finally, the named inventors of parent application U.S. Ser. No. 08/788,800 and parent provisional application U.S. Ser. No. 60/093,038 are Martin M. Bednar, Cordell E. Gross and G. Roger Thomas. Thus, there is continuity of inventorship throughout the chain of applications extending from the above-identified application to parent provisional application U.S. Ser. No. 60/093,038.

Claim 1 (and all of its dependent claims) in the above-identified application recite a method for “increasing cerebral blood flow and/or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery in a human mammal which comprises the step of co-administering effective amounts of tissue plasminogen activator (tPA) and anti-CD18 antibody to the mammal wherein neither the tPA nor the anti-CD18 antibody is administered to the mammal until about three to five hours after the onset of focal ischemic stroke”, as supported, at least, on page 5, line 31 to page 6, line 12 and page 29, lines 10-16 of the specification and in Figures 1-2 of the above-identified application; on page 5, line 31 to page 6, line 12 and page 29, lines 10-16 of the specification and in Figures 1-2 of parent application U.S. Ser. No. 08/788,800 (and by the same disclosure incorporated by reference in parent application U.S. Ser. No. 09/251,652); and on page 6, lines 12-27 and page 33, line 27 to page 34, line 4 of the specification and in Figures 1 and 2 of parent provisional application U.S. Ser. No. 60/093,038.

Since the above-identified application satisfies the requirements of co-pendency and continuity of disclosure and inventorship, and since the pending claims in the application are supported by the disclosures of every parent in the chain of applications beginning with

¹ Provisional application U.S. Ser. No. 60/093,038 was converted from non-provisional application U.S. Ser. No. 08/589,982 by petition under 37 C.F.R. §1.53 filed on January 14, 1997 and granted on July 31, 1998.


provisional application U.S. Ser. No. 60/093,038, as shown above, Applicants submit that the pending claims in above-identified application are entitled to claim priority to provisional application U.S. Ser. No. 60/093,038 filed January 23, 1996. Accordingly, Applicants hereby claim priority to provisional application U.S. Ser. No. 60/093,038 filed January 23, 1996.

Applicants respectfully submit that the application is in condition for examination.

Respectfully submitted,

GENENTECH, INC.

Date: December 20, 2000

By: 
Richard B. Love
Reg. No. 34,659

One DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881